New drugs from old

Drug and Therapeutics Bulletin

Volumn 44, Issue 10, 2006, Pages 73-77

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS VITAMIN D; AMITRIPTYLINE; BECLOMETASONE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBAMAZEPINE; CETIRIZINE; CITALOPRAM; DESLORATADINE; DOXAZOSIN; ESCITALOPRAM; ESOMEPRAZOLE; FLOMAXTRA; FLUTICASONE PROPIONATE PLUS SALMETEROL; FOSAVANCE; GABAPENTIN; LEVOCETIRIZINE; LITHIUM SALT; LORATADINE; MIRTAZAPINE; MORPHINE; NIFEDIPINE; OMEPRAZOLE; PAROXETINE; PREGABALIN; RAMIPRIL; SERTRALINE; TAMSULOSIN; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ANALGESIC ACTIVITY; ARTICLE; ASTHMA; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG LEGISLATION; DRUG MARKETING; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPSY; GASTROESOPHAGEAL REFLUX; GENERALIZED ANXIETY DISORDER; HAY FEVER; HUMAN; HYPERTENSION; HYPOTENSION; LEGAL ASPECT; NATIONAL HEALTH SERVICE; NEUROPATHIC PAIN; OSTEOPOROSIS; PATENT; PHARMACY; PROSTATE HYPERTROPHY; SOMNOLENCE; UNITED KINGDOM; URTICARIA;

EID: 33750088964     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2006.441073     Document Type: Article

References (29)

1. Office of Health Economics. Compendium of Health Statistics 2005-2006. Oxford: Radcliffe Publishing Ltd, 2005.
2. House of Commons Health Committee, 2005. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004-05. HC 42-I [online]. London: The Stationery Office Limited. Available: http:// www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf [Accessed 20 September 2006].
3. Brodie I. Product lifecycling. PharmaTimes 2005; February: 30-2.
4. Bellingham C. Is patent extension good for patients? Pharm J 2001; 267: 775-6.
5. Association of British Pharmaceutical Industry, 2003. Clinical trials - developing new medicines [online]. Available: http://www.abpi.org.uk/ publications/pdfs/clinical_brief.pdf [Accessed 20 September 2006].
6. Lloyd I. R&D development remains just around the corner. Scrip Magazine 2002; 109: 72-3.
7. European Parliament Directive 2004/27/EC.
8. Garattini S, Bertele S. Adjusting Europe's drug regulation to public health needs. Lancet 2001; 358: 64-7.
9. National Institute for Health Care Management Foundation. Changing patterns of pharmaceutical innovation. Washington: NIHCM Foundation, 2002.
10. Drugs in 2001. Prescrire Int 2002; 11: 58-60.
11. European Generic medicines Association, 2003. A bitter pill to swallow. Myths and realities of the pharmaceutical industry [online]. Available: http://www.egagenerics.com/doc/ega_myths-reality.pdf [Accessed 20 September 2006].
12. IMS, 2000. What is a Supplementary Protection Certificate? [online]. Available:www.ims-global.com/insight/news_story/ news_story_000417b.htm [Accessed 20 September 2006].
13. Department of Health and ABPI, 2004. The Pharmaceutical Price Regulation Scheme 2005 [online]. Available: http://www.dh.gov.uk/assetRoot/04/09/32/ 32/04093232.pdf [Accessed 20 September 2006].
14. Cardura XL. Summary of product characteristics, UK. Pfizer Limited, March 2005.
15. Chung M et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-87.
16. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1999; 33: 791-7.
17. Tucker GT. Chiral switches. Lancet 2000; 355: 1085-7.
18. Therapeutics Initiative. Do single stereoisomer drugs provide value? Therapeutics Letter 2002; 45.
19. Xyzal. Summary of product characteristics, UK. UCB Pharma Limited, February 2006.
20. Svensson S, Mansfield P. Escitalopram: Superior to citalopram or a chiral chimera? Psychother Psychosom 2004; 73: 10-6.
21. Dyer O. Lundbeck broke advertising rules. BMJ 2003; 326: 1004.
22. Moore N et al. Prospective, multicentre, randomised, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131-7.
23. National Prescribing Centre. Escitalopram or citalopram for depression in primary care. MeReC Extra 2005; 18.
24. Lepola UM et al. Escitalopram (10-20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-7.
25. Colonna L et al. A randomised, double-blind, 24-week study of escitalopram (10mg/day) versus citalopram (20mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005; 21: 1659-68.
26. London New Drugs Group. Tactics to prolong market exclusivity of blockbuster products - implications for the NHS. APC/DTC Briefing, January 2002.
27. European Medicines Agency (EMEA), 2004. European Public Assessment Report (EPAR) - Lyrica [online]. Available: http://www.emea.eu.int/ humandocs/Humans/EPAR/lyrica/lyrica.htm [Accessed 20 September 2006].
28. Lyrica. Summary of product characteristics, UK Pfizer Limited, December 2005.
29. Drug treatment of neuropathic pain. DTB 2000; 38: 89-93.